CN101519401B - Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof - Google Patents
Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof Download PDFInfo
- Publication number
- CN101519401B CN101519401B CN 200810033932 CN200810033932A CN101519401B CN 101519401 B CN101519401 B CN 101519401B CN 200810033932 CN200810033932 CN 200810033932 CN 200810033932 A CN200810033932 A CN 200810033932A CN 101519401 B CN101519401 B CN 101519401B
- Authority
- CN
- China
- Prior art keywords
- thiophene
- para
- methyl ester
- tartrate
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 COC(C(c1ccccc1Cl)N)=* Chemical compound COC(C(c1ccccc1Cl)N)=* 0.000 description 4
- UTWOZNRDJNWTPS-UHFFFAOYSA-N COC(C(c(cccc1)c1Cl)N)=O Chemical compound COC(C(c(cccc1)c1Cl)N)=O UTWOZNRDJNWTPS-UHFFFAOYSA-N 0.000 description 1
- LMIZLNPFTRQPSF-UHFFFAOYSA-N NC(C(O)=O)c1ccccc1Cl Chemical compound NC(C(O)=O)c1ccccc1Cl LMIZLNPFTRQPSF-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
The invention relates to an intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and the preparation of salts thereof. The invention improves the existing technologyThe invention relates to an intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and the preparation of salts thereof. The invention improves the existing technology of preparing the intermediate and the salts thereof, and adopts (S)-(+)-chlorophenylglycine methyl ester L-tartrate as raw materials which directly react with p-substituted thiofuran benzenesulphonatof preparing the intermediate and the salts thereof, and adopts (S)-(+)-chlorophenylglycine methyl ester L-tartrate as raw materials which directly react with p-substituted thiofuran benzenesulphonat e-2-ethyl esters compounds for preparing the intermediate. Compared with the prior art, the improved method has the advantages that the raw materials and reagents are cheap and easily available, the pe-2-ethyl esters compounds for preparing the intermediate. Compared with the prior art, the improved method has the advantages that the raw materials and reagents are cheap and easily available, the production yield is high, the optical purity of the product is high, the technological operation is simple, and the like, thus being a method for commercially producing the intermediate of clopidogrel roduction yield is high, the optical purity of the product is high, the technological operation is simple, and the like, thus being a method for commercially producing the intermediate of clopidogrel and salts thereof. and salts thereof.
Description
Technical field
The present invention relates to the preparation of clopidogrel intermediate (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof.
Background technology
Clopidogrel (Clopidogrel); Chemistry (S)-α by name-(2-chloro-phenyl-)-6; 7-dihydro-thiophene also [3; 2-c] pyridine-5 (4H)-methyl acetate, be anticoagulant of new generation, be mainly used in treatment arteriosclerosis disease, acute coronary syndrome, prevention intracoronary stent and plant people's postoperative in-stent restenosis and thrombotic complications etc.
Up to now, the relevant method for preparing clopidogrel has a lot, and midbody (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof are its important midbodys, and the method for synthetic this midbody of report mainly contains following several kinds:
Patent (EP.Pat.No.466569 US.Pat.No.5204469) adopts following route:
With o-chlorobenzaldehyde and sodium cyanide and azanol reaction generation alpha-amino group (2-chlorine) toluylic acid, with tosic acid thiophene-2-ethyl ester reaction, split then after the esterification, make this midbody.Use this route, obtain very difficulty of single enantiomer, because the easy racemization of this midbody; And, long reaction time (40h), yield also low (50%).
Patent (US.Pat.No.6080875) report:
Split alpha-amino group (2-chlorine) methyl phenylacetate earlier, under the catalysis of acetate, react this midbody of generation with thiophene-2-glycidic acid sodium and cyaniding Peng Qinghuana then.Though it is higher that this route respectively goes on foot yield, agents useful for same cyaniding Peng Qinghuana is not easy to obtain, and raw material thiophene-2-glycidic acid sodium is difficult to preparation, and cost is high.
Patent (US.Pat.No.4529596 US.Pat.No.4847265) report:
With (S)-(+)-O-chlorobenzene glycine methyl ester; With tosic acid thiophene-this midbody of 2-ethyl ester preparation, because (S)-(+)-O-chlorobenzene glycine methyl ester racemization in reaction easily, so the optical purity of product is difficult to be protected; Specific rotation is low, is difficult to prepare qualified clopidogrel.
In sum, now general synthetic this midbody all is to react with (S)-(+)-O-chlorobenzene glycine methyl ester, but its easy racemization, influences the optical purity of product, and this patent provides a kind of new method to prepare this midbody and salt thereof.
Summary of the invention
The objective of the invention is to, the compound method of a kind of improved clopidogrel intermediate (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof is provided.
The present invention has done improvement to the preparation of (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof.
With (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound prepared in reaction (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof; Its key step is: with (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate is starting raw material; Without the monomer that dissociates (S)-(+)-O-chlorobenzene glycine methyl ester, but directly and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound under alkaline condition, carry out condensation reaction; Products therefrom is through the acidifying salify, and reaction equation is following:
(S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof synthetic
Said condensation reaction is performed such:
(S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound are placed there-necked flask; Do not add or add a spot of solvent; In 20-150 ℃ (preferred 75-110 ℃), reaction 1-24hr (preferred 5-20hr) obtains this midbody;
Wherein said solvent is water, methyl alcohol, ethanol, acetonitrile, DMF; Used alkali is that the oxyhydroxide of basic metal or earth alkali metal and ammonium class is (like KOH, NaOH, Ba (OH)
2Or Ca (OH)
2), or the carbonate of basic metal or earth alkali metal and ammonium class is (like Na
2CO
3, K
2CO
3, NaHCO
3, KHCO
3, (NH
4)
2CO
3, (NH
4) HCO
3); Or alkali is that the phosphoric acid salt of basic metal or earth alkali metal and ammonium class is (like Na
3PO
4, Na
2HPO
4, NaH
2PO
4, K
3PO
4, K
2HPO
4, KH
2PO
4, (NH
4)
2HPO
4, (NH
4) H
2PO
4), or alkali is the phosphite such as the Na of basic metal or earth alkali metal and ammonium class
3PO
3, Na
2HPO
3, NaH
2PO
3, K
3PO
3, K
2HPO
3, KH
2PO
3, (NH
4)
2HPO
3, (NH
4) H
2PO
3), (S)-(+)-mol ratio (1) of O-chlorobenzene glycine methyl ester L-tartrate, para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound, alkali: (1.1-1.8): (1.2-6.0), (preferred molar ratio (1): (1.3-1.6): (1.6-5.6)).
Said salt-forming reaction is performed such:
In above-mentioned condensation reaction thing, add entry and ETHYLE ACETATE, separatory; In organic layer, drip acid solution, under insulation and agitation condition, the reaction times is 1-8hr (preferred 2-6hr), the after-filtration drying obtains this intermediate salt.
Wherein used acid is hydrochloric acid, sulfuric acid, formic acid, acetate (HCl, H
2SO
4, HCOOH, CH
3COOH).
The used starting raw material para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound of the present invention can be made by corresponding para-orientation benzene sulfonyl chloride compounds and thiophene ethanol.Concrete steps are referring to patent EP466569.
In preferred version of the present invention, in para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound-R is :-H ,-CH
3,-C
12H
25,-CH=CH
2,-NO
2,-Br ,-a kind of among the Cl, the best is-H ,-CH
3
About the report of clopidogrel,, find that the patent content relevant with the present invention is following: US.Pat.No.5204469, US.PatNo.20040073057, WO.Pat.No.2006/003671A1 both at home and abroad through self check and the retrieval of service center of patent office searching.
The present invention improves some principal reaction technologies in the prior art, has obtained good effect, and principal character is following:
1, in carrying out condensation reaction; Existing processing condition (referring to patent EP466569); (S)-(+) after adopt splitting-O-chlorobenzene glycine methyl ester L-tartrate earlier with the alkali neutralization, boil off solvent through separatory, extraction, thin film evaporation and obtain (S)-(+)-O-chlorobenzene glycine methyl ester; Condensation obtains this midbody again, obtains its salt through acidifying.The present invention has adopted without neutralization, separatory, has extracted, revolved steaming, the free step that obtains (S)-(+)-O-chlorobenzene glycine methyl ester; But adopt (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate as raw material; Direct and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound reacts; Condensation obtains title product again, becomes its salt after the acidifying.
2, the present invention avoids free (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate to generate (S)-(+)-O-chlorobenzene glycine methyl ester, because (S)-(+)-easy racemization and the instability of taking place of O-chlorobenzene glycine methyl ester.Method of the present invention is simplified step of condensation, shortens the reaction times, thereby the product prepn cycle is shortened dramatically, and raises the efficiency.
Advantages such as in sum, technical scheme provided by the present invention has easy and simple to handle, and yield is higher, and the opticity maintenance is better are a kind of methods that is easy to commercialization preparation (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof.
Embodiment
Embodiment 1 is that (5.00g, 0.0143mol) (5.00g 0.0177mol) places there-necked flask, adds K with tosic acid thiophene-2-ethyl ester for (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate of 94 ° with optically-active
2HPO
43H
2O (18.50g), 97-99 ℃ of reaction 12hr, reaction adds water (50ml), ETHYLE ACETATE (40ml) after finishing; Stirring, separatory extract organic layer, and concentrated hydrochloric acid is regulated between the PH:1.2-1.5, the ice-water bath cold filtration; Obtain the 4.08g product, mp:181.6-181.8 ℃, [α]
D 25=+109.4 ° of (c=1.0, CH
3OH);
Yield: 82.5%.
1HNMR (D
2O, 500MHz), δ: 7.65～7.51 (m, 4H), 7.30 (t, J=3.5Hz, 1H), 6.98 (t, J=3.5Hz, 2H), 5.75 (s, 1H), 3.85 (s, 3H), 3.84～3.12 (m, and 4H) (literature value: mp:180-182 ℃, [α]
D 25=+108.5-110 °).
With above-mentioned products therefrom 4.00g, 8ml methyl alcohol, 26ml formaldehyde (37%); Join in the there-necked flask that stirring, reflux are housed; According to the reaction of patent (US.Pat.No.4529596 US.Pat.No.4847265) process step, obtain the 3.48g white solid, 181.7 ℃ of fusing points (incipient melting); HPLC:99.2%, yield 71.6%.I type SR-25990C for qualified meets standards of pharmacopoeia.
Embodiment 2 is that (5.00g, 0.0143mol) (5.00g 0.0177mol) places there-necked flask, adds Na with tosic acid thiophene-2-ethyl ester for (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate of 94 ° with optically-active
2CO
3(3.70g), water (1ml), at 96-99 ℃ of reaction 11hr, after reaction finishes, add water (50ml), ETHYLE ACETATE (40ml); Stirring, separatory extract organic layer, and concentrated hydrochloric acid is regulated between the PH:1.2-1.5, the ice-water bath cold filtration; Obtain the 4.03g product, mp:180.0-180.2 ℃, [α]
D 25=+108.7 ° of (c=1.0, CH
3OH), yield: 81.5%.
Embodiment 3 is that (5.00g, 0.0143mol) (5.00g 0.0177mol) places there-necked flask, adds Na with Phenylsulfonic acid thiophene-2-ethyl ester for (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate of 94 ° with optically-active
2HPO
412H
2O (13g), Na
2CO
3(2.60g), at 94-99 ℃ of reaction 13hr, after reaction finishes, add water (50ml), ETHYLE ACETATE (40ml), stir, separatory; Extract organic layer, concentrated hydrochloric acid is regulated between the PH:1.2-1.5, the ice-water bath cold filtration; Obtain the 4.00g product, mp:179.8-180.1 ℃, [α]
D 25=+107.5 ° of (c=1.0, CH
3OH), yield: 80.9%.
Adopt with embodiment 1 similar synthetic route under different technology conditions, to prepare (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate and salt thereof, its result sees table 1:
Table 1
Claims (4)
1. the preparation method of a clopidogrel intermediate (S)-2-(2 thiophene ethyl amine base) (2-chloro-phenyl-) methyl acetate salt; It is characterized in that; With (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate is starting raw material; Without the monomer that dissociates (S)-(+)-O-chlorobenzene glycine methyl ester, but directly and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound under alkaline condition, carry out condensation reaction, products therefrom is salify after acidifying;
Said condensation reaction is performed such:
(S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound are placed there-necked flask, do not add or add a spot of solvent, in 20-150 ℃, reaction 1-24hr obtains this midbody;
Wherein said solvent is water, methyl alcohol, ethanol, acetonitrile, DMF; Said alkali is the oxyhydroxide of basic metal or earth alkali metal and ammonium class, or the carbonate of basic metal or earth alkali metal and ammonium class; Or the phosphoric acid salt of basic metal or earth alkali metal and ammonium class;
Said oxyhydroxide is KOH, NaOH, Ba (OH)
2Or Ca (OH)
2Said carbonate is Na
2CO
3, K
2C0
3, NaHC0
3, KHC0
3, (NH
4)
2C0
3, (NH
4) HC0
3Said phosphoric acid salt is Na
3P0
4, Na
2HP0
4, K
3P0
4, K
2HP0
4, (NH
4) H
2P0
4, (NH
4)
2HP0
4
Said salt-forming reaction is performed such:
In above-mentioned condensation reaction thing, add entry and ETHYLE ACETATE, separatory in organic layer, drips acid solution, and under insulation and agitation condition, salt time is 1-8hr, and filtration drying obtains this intermediate salt; Wherein, used acid is hydrochloric acid, sulfuric acid, formic acid, acetate;
In said para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound para-orienting group be-H ,-CH
3,-C
12H
25,-CH=CH
2,-NO
2,-Br ,-a kind of among the Cl.
2. the preparation method described in claim 1 is characterized in that, (S)-(+)-and the temperature of reaction of O-chlorobenzene glycine methyl ester L-tartrate and para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound is 75-110 ℃.
3. the preparation method described in claim 1 is characterized in that, the mol ratio of raw material consumption is (S)-(+)-O-chlorobenzene glycine methyl ester L-tartrate: para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound: alkali=1:1.1-1.8:1.2-6.0.
4. the preparation method described in claim 3 is characterized in that, the mol ratio of raw material consumption is the O-chlorobenzene glycine methyl ester L-of (S)-(+) tartrate: para-orientation Phenylsulfonic acid thiophene-2-ethyl ester compound: alkali=1:1.3-1.6:1.6-5.6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810033932 CN101519401B (en) | 2008-02-27 | 2008-02-27 | Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810033932 CN101519401B (en) | 2008-02-27 | 2008-02-27 | Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101519401A CN101519401A (en) | 2009-09-02 |
| CN101519401B true CN101519401B (en) | 2012-12-05 |
Family
ID=41080224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810033932 Active CN101519401B (en) | 2008-02-27 | 2008-02-27 | Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101519401B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103172527A (en) * | 2011-12-26 | 2013-06-26 | 湖北德洲科技发展有限公司 | Method for preparing clopidogrel synthetic intermediate-L-2-chlorophenylglycine methyl ester |
| CN103980288A (en) * | 2014-06-03 | 2014-08-13 | 成都医路康医学技术服务有限公司 | Production process of clopidogrel |
| CN110862372B (en) * | 2019-12-03 | 2024-01-12 | 江西川奇药业有限公司 | Synthesis of clopidogrel intermediate (S) -2- (2-thiophenoethylamine) - (2-chlorophenyl) -methyl acetate |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100999525A (en) * | 2006-10-18 | 2007-07-18 | 深圳信立泰药业有限公司 | Preparation process of clopidogre and its salt |
-
2008
- 2008-02-27 CN CN 200810033932 patent/CN101519401B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100999525A (en) * | 2006-10-18 | 2007-07-18 | 深圳信立泰药业有限公司 | Preparation process of clopidogre and its salt |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101519401A (en) | 2009-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514018A (en) | Stable salts of novel derivatives of 3,3-diphenylpropylamines | |
| JP4283896B2 (en) | Method for producing 2-thienylethylamine derivative | |
| US20080097101A1 (en) | Industrial process for preparation of clopidogrel hydrogen sulphate | |
| CN101519401B (en) | Intermediate (S)-2-(2-thiophene ethylamine)(2-chlorphenyl)methyl acetate of clopidogrel and method for preparing salts thereof | |
| US7692015B2 (en) | Economical process for preparing (S, S)-2, 8-diazabicyclo[4.3.0]nonane and its enantiomer | |
| PL178720B1 (en) | Method of obtaining azabicyclic derivatives | |
| CN102382033A (en) | Preparation methods for optical activity mitiglinide ester and mitiglinide salt | |
| US7381835B2 (en) | Resolution process for (R)-(-)-2-hydroxy-2-(2-chlorophenyl) acetic acid | |
| US20050143414A1 (en) | Process for the preparation of clopidogrel | |
| JP2004511477A (en) | Synthesis of R (+) α-lipoic acid | |
| RU2006143986A (en) | METHOD FOR PRODUCING ARYLOXICARBOXYLIC ACIDS | |
| KR101755291B1 (en) | Process for the preparation of thyroid hormones and salts thereof | |
| EP2423178A1 (en) | Process for the production of sitagliptin | |
| KR20110086723A (en) | Process for resolving zopiclone | |
| EP2316817A1 (en) | Process for the preparation of fesoterodine | |
| US6346649B1 (en) | Process for the recovery and recycle of D-tartaric acid | |
| EP1242353A1 (en) | Process for the recovery and recycle of d-tartaric acid | |
| JP2010530397A (en) | Method for improving amide formation | |
| KR20140135658A (en) | Process for the synthesis of 3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | |
| JP6234999B2 (en) | Process for preparing optically active 3,3-diphenylpropylamine | |
| JP3333184B2 (en) | Process for producing (S) -3,4-epoxybutyrate having optical activity | |
| WO2006003671A1 (en) | A process for resolution of methylamino(2-chlorophenyl)acetate | |
| CZ20011043A3 (en) | Diastereomeric salts of (+)- or (-)-alpha-(difluoromethyl)ornithine and process for preparing (-)-alpha-(difluoromethyl)ornithine-monohydrochloride monohydrate | |
| US8367827B2 (en) | Process for preparing hydrocodone using a super acid | |
| EP1315701B1 (en) | Process for the racemisation of 1-benzyl-4-(4-fluorophenyl)-3-hydroxymethyl-1,2,3,6-tetrahydropyridine to be used as intermediate in the synthesis of paroxetine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090902 Assignee: Jiangsu Baju Pharmaceutical Co., Ltd. Assignor: East China University of Science and Technology|Shanghai Huali biopharmaceutical Co Ltd Contract record no.: 2014320000198 Denomination of invention: Preparation of clopidogrel intermediate (S) -2- (2- thiophene) (2- chloro) methyl acetate and its salts Granted publication date: 20121205 License type: Exclusive License Record date: 20140311 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 200231 four floor, block B, 18 lane, 1305 lane, Huajing Road, Shanghai. Co-patentee after: East China University of Science and Technology Patentee after: Shanghai Huali bio medicine Limited by Share Ltd Address before: 200231 four floor, block B, 18 lane, 1305 lane, Huajing Road, Shanghai. Co-patentee before: East China University of Science and Technology Patentee before: Shanghai Huali Biopharmaceutical Co., Ltd. |